Nucleic Acid Therapeutics CDMO Market To Reach $33.86 Billion By 2030

Nucleic Acid Therapeutics CDMO Market Growth & Trends

The global nucleic acid therapeutics CDMO market size is expected to reach USD 33.86 billion by 2030, registering a CAGR of 14.10% during the forecast period, according to a new report by Grand View Research, Inc. The market's growth is primarily attributed to factors such as increasing demand for nucleic acid therapeutics, advancements in nucleic acid technologies, and rising FDA approvals of nucleic acid therapeutics, propelling the need for cost-effective contract development and manufacturing services.

Growing investment and interest in gene therapy research and development by biotechnology companies, pharmaceutical firms, and academic institutions are driving the demand for CDMO services. CDMOs have played a crucial role in gene therapy manufacturing. For instance, Catalent has taken on the primary role as the commercial manufacturing partner for Sarepta Therapeutics in their efforts to advance gene therapy solutions.

The success of mRNA vaccines in responding to the COVID-19 pandemic has showcased the potential of nucleic acid therapeutics, stimulating further research and investment in this field. For instance, in March 2022, Sanofi announced that it plans to allocate USD 1.02 billion (935 million euros) for the development of messenger RNA vaccines in France over the coming years. Sanofi intends to allocate this investment until 2026 as a part of a 2-billion-euro global investment initiative unveiled in June 2021. This initiative is designed to expedite the company's mRNA strategy. Such increased funding scenarios drive market growth.

Furthermore, increasing incidences of CDMO acquisitions and partnerships are expected to accelerate the market growth for nucleic acid therapeutics CDMO in the coming years. For instance, in May 2022, eureKARE initiated a merger worth USD 160.98 million (€150 million) to create a cell & gene therapy contract development and manufacturing organization (CDMO).

The company has established eureKING, a Special Purpose Acquisition Company (SPAC), with the aim of merging three European Contract Development and Manufacturing Organizations (CDMOs) into a unified entity. In another instance, in April 2022, Fujifilm broadened its Advanced Therapies Contract Development and Manufacturing Organization (CDMO) portfolio by acquiring a specialized cell therapy manufacturing facility from Atara Biotherapeutics, Inc. located in California. Such initiatives are expected to boost market growth.

 Request a free sample copy or view report summary: Nucleic Acid Therapeutics CDMO Market Report

Nucleic Acid Therapeutics CDMO Market Report Highlights

• The RNA-based therapies segment held the largest revenue share in 2023. RNA-based therapies, mainly mRNA, offer versatility in addressing various diseases. They can be designed to produce a variety of therapeutic proteins, making them applicable to diverse therapeutic areas.

• The gene therapy segment is expected to show significant market growth in the coming years. This is attributed to the clinical success of gene therapies, which have helped in expanding indications of gene therapies.

• In 2023, the manufacturing services segment dominated the market, accounting for over 38.37% of the total revenue share. Key factors contributing to segment growth include complex manufacturing processes, scale-up & production challenges, and cost efficiency.

• The biotechnology companies held a major revenue share of over 58% in 2023 due to substantial investments in the research and development of innovative therapies.

• North America held the largest revenue share of 40.24% in the nucleic acid therapeutic CDMO market in 2023. Substantial investments and funding support, strong academic and research institutions, and global expansion of CDMOs drive regional growth.

Nucleic Acid Therapeutics CDMO Market Segmentation

Grand View Research has segmented the global nucleic acid therapeutics CDMO market report based on type, service, end-use, application, and region:

Nucleic Acid Therapeutics CDMO Type Outlook (Revenue, USD Million, 2018 - 2030)

• Gene Therapy

• RNA-based Therapies

Nucleic Acid Therapeutics CDMO Service Outlook (Revenue, USD Million, 2018 - 2030)

• Process Development and Optimization

• Manufacturing Services

• Analytical and Quality Control Services

• Others

Nucleic Acid Therapeutics CDMO End Use Outlook (Revenue, USD Million, 2018 - 2030)

• Pharmaceutical Companies

• Government & Academic Research Institutes

• Biotech Companies

Nucleic Acid Therapeutics CDMO Application Outlook (Revenue, USD Million, 2018 - 2030)

• Rare Diseases

• Genetic Disorders

• Infectious Diseases

• Others

Nucleic Acid Therapeutics CDMO Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Nucleic Acid Therapeutics CDMO Market

• Agilent Technologies, Inc.

• Curia Global, Inc.

• Ajinomoto Co., Inc.

• Danaher (Aldevron)

• KNC Laboratories Co., Ltd.

• LGC Limited

• Merck KGaA

• WuXi AppTec

• BIOSPRING

• Univercells Inc.

• Exothera